Experts Struggle to Agree on How to Measure Whether PRRT Cancer Treatment Is Working
ENETS expert survey reveals major gaps and disagreements in how to assess response to peptide receptor radionuclide therapy for neuroendocrine tumors.
Quick Facts
What This Study Found
Expert survey revealed significant variability and unmet needs in PRRT response assessment, with no consensus on standardized criteria.
Key Numbers
70% of Advisory Board responded; 81% from ENETS Centers of Excellence; 13 questions; 46% achieved >75% agreement; 39% achieved >60% agreement.
How They Did This
Statement-based survey of ENETS Advisory Board members (70% response rate) with 13 questions and substatements.
Why This Research Matters
Without standardized response criteria, clinicians cannot reliably compare PRRT outcomes across centers or decide when to stop or modify treatment.
The Bigger Picture
Standardizing PRRT response assessment would improve clinical trials, enable better comparisons, and ultimately improve patient care.
What This Study Doesn't Tell Us
Expert survey — reflects opinions rather than evidence. Response criteria have not yet been validated prospectively.
Questions This Raises
- ?Should functional imaging replace morphological criteria for PRRT response?
- ?Can molecular markers complement imaging for earlier response assessment?
Trust & Context
- Key Stat:
- 70% response ENETS Advisory Board survey on PRRT response assessment practices and unmet needs
- Evidence Grade:
- Expert consensus survey — captures current practice variability but does not provide validated criteria.
- Study Age:
- Published in 2025 from the 2022 ENETS meeting, reflecting ongoing efforts to standardize PRRT assessment.
- Original Title:
- Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force.
- Published In:
- Journal of neuroendocrinology, 37(2), e13479 (2025)
- Authors:
- Prasad, Vikas, Koumarianou, Anna, Denecke, Timm, Sundin, Anders, Deroose, Christophe M, Pavel, Marianne, Christ, Emanuel, Lamarca, Angela, Caplin, Martyn, Castaño, Justo P, Dromain, Clarisse, Falconi, Massimo, Grozinsky-Glasberg, Simona, Hofland, Johannes, Knigge, Ulrich Peter, Kos-Kudla, Beata, Krishna, Balkundi A, Reed, Nicholas Simon, Scarpa, Aldo, Srirajaskanthan, Rajaventhan, Toumpanakis, Christos, Kjaer, Andreas, Hicks, Rodney J, Ambrosini, Valentina
- Database ID:
- RPEP-13106
Evidence Hierarchy
Frequently Asked Questions
How do doctors know if PRRT is working?
This is actually a major challenge — tumors may not shrink immediately after PRRT, and current measurement criteria were designed for other treatments.
Why are standardized criteria important?
Without agreed-upon measures, different hospitals may reach different conclusions about whether treatment is working, affecting patient care decisions.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13106APA
Prasad, Vikas; Koumarianou, Anna; Denecke, Timm; Sundin, Anders; Deroose, Christophe M; Pavel, Marianne; Christ, Emanuel; Lamarca, Angela; Caplin, Martyn; Castaño, Justo P; Dromain, Clarisse; Falconi, Massimo; Grozinsky-Glasberg, Simona; Hofland, Johannes; Knigge, Ulrich Peter; Kos-Kudla, Beata; Krishna, Balkundi A; Reed, Nicholas Simon; Scarpa, Aldo; Srirajaskanthan, Rajaventhan; Toumpanakis, Christos; Kjaer, Andreas; Hicks, Rodney J; Ambrosini, Valentina. (2025). Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force.. Journal of neuroendocrinology, 37(2), e13479. https://doi.org/10.1111/jne.13479
MLA
Prasad, Vikas, et al. "Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force.." Journal of neuroendocrinology, 2025. https://doi.org/10.1111/jne.13479
RethinkPeptides
RethinkPeptides Research Database. "Challenges in developing response evaluation criteria for pe..." RPEP-13106. Retrieved from https://rethinkpeptides.com/research/prasad-2025-challenges-in-developing-response
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.